JP2019526555A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526555A5 JP2019526555A5 JP2019508973A JP2019508973A JP2019526555A5 JP 2019526555 A5 JP2019526555 A5 JP 2019526555A5 JP 2019508973 A JP2019508973 A JP 2019508973A JP 2019508973 A JP2019508973 A JP 2019508973A JP 2019526555 A5 JP2019526555 A5 JP 2019526555A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- formula
- hydrogen
- glutathione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 112
- 229910052739 hydrogen Inorganic materials 0.000 claims 76
- 239000001257 hydrogen Substances 0.000 claims 76
- 150000002431 hydrogen Chemical class 0.000 claims 65
- 125000001931 aliphatic group Chemical group 0.000 claims 58
- 108010024636 Glutathione Proteins 0.000 claims 56
- 229960003180 glutathione Drugs 0.000 claims 56
- 125000003118 aryl group Chemical group 0.000 claims 55
- 125000000623 heterocyclic group Chemical group 0.000 claims 54
- 239000002773 nucleotide Substances 0.000 claims 53
- 125000003729 nucleotide group Chemical group 0.000 claims 53
- 229910052760 oxygen Inorganic materials 0.000 claims 53
- 125000001072 heteroaryl group Chemical group 0.000 claims 51
- 108091034117 Oligonucleotide Proteins 0.000 claims 46
- 229910052717 sulfur Inorganic materials 0.000 claims 39
- 229910052736 halogen Inorganic materials 0.000 claims 31
- 150000002367 halogens Chemical class 0.000 claims 31
- 239000002777 nucleoside Substances 0.000 claims 30
- 125000000753 cycloalkyl group Chemical group 0.000 claims 29
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 18
- 125000005647 linker group Chemical group 0.000 claims 17
- -1 nitro, amino Chemical group 0.000 claims 14
- 239000003446 ligand Substances 0.000 claims 13
- 150000008300 phosphoramidites Chemical class 0.000 claims 13
- 125000006850 spacer group Chemical group 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 239000007787 solid Substances 0.000 claims 10
- 125000006239 protecting group Chemical group 0.000 claims 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 7
- 125000005842 heteroatom Chemical group 0.000 claims 7
- 229910019142 PO4 Inorganic materials 0.000 claims 6
- 108091030071 RNAI Proteins 0.000 claims 6
- 230000000692 anti-sense effect Effects 0.000 claims 6
- 230000009368 gene silencing by RNA Effects 0.000 claims 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 6
- 239000010452 phosphate Substances 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 5
- 229910052711 selenium Inorganic materials 0.000 claims 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000004434 sulfur atom Chemical group 0.000 claims 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 3
- 108091081021 Sense strand Proteins 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 2
- 150000008298 phosphoramidates Chemical class 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 101150084233 ago2 gene Proteins 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000002427 irreversible effect Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- 125000004437 phosphorous atom Chemical group 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022076983A JP2022106928A (ja) | 2016-08-23 | 2022-05-09 | 可逆的に修飾されたオリゴヌクレオチドを含む組成物及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378635P | 2016-08-23 | 2016-08-23 | |
| US62/378,635 | 2016-08-23 | ||
| PCT/US2017/048239 WO2018039364A1 (en) | 2016-08-23 | 2017-08-23 | Compositions comprising reversibly modified oligonucleotides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022076983A Division JP2022106928A (ja) | 2016-08-23 | 2022-05-09 | 可逆的に修飾されたオリゴヌクレオチドを含む組成物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526555A JP2019526555A (ja) | 2019-09-19 |
| JP2019526555A5 true JP2019526555A5 (https=) | 2020-10-01 |
| JP7249080B2 JP7249080B2 (ja) | 2023-03-30 |
Family
ID=61245366
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508973A Active JP7249080B2 (ja) | 2016-08-23 | 2017-08-23 | 可逆的に修飾されたオリゴヌクレオチドを含む組成物及びその使用 |
| JP2022076983A Withdrawn JP2022106928A (ja) | 2016-08-23 | 2022-05-09 | 可逆的に修飾されたオリゴヌクレオチドを含む組成物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022076983A Withdrawn JP2022106928A (ja) | 2016-08-23 | 2022-05-09 | 可逆的に修飾されたオリゴヌクレオチドを含む組成物及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11390642B2 (https=) |
| EP (1) | EP3503730B1 (https=) |
| JP (2) | JP7249080B2 (https=) |
| KR (1) | KR102530513B1 (https=) |
| CN (2) | CN109890207B (https=) |
| AU (2) | AU2017315670B2 (https=) |
| CA (1) | CA3032165C (https=) |
| IL (2) | IL264685B (https=) |
| MX (2) | MX2019002075A (https=) |
| WO (1) | WO2018039364A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102350647B1 (ko) * | 2016-09-02 | 2022-01-14 | 다이서나 파마수이티컬, 인크. | 4'-포스페이트 유사체 및 이를 포함하는 올리고뉴클레오타이드 |
| EP3697423A4 (en) | 2018-01-05 | 2021-08-11 | Dicerna Pharmaceuticals, Inc. | REDUCED EXPRESSION OF BETA-CATENIN AND IDO TO POTENTIALIZE IMMUNOTHERAPY |
| WO2019143621A1 (en) | 2018-01-16 | 2019-07-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting aldh2 expression |
| CA3135402A1 (en) | 2019-04-04 | 2020-10-08 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression in the central nervous system |
| EP4116422A4 (en) * | 2020-03-03 | 2024-03-20 | Nexmos Co., Ltd. | Dna aptamer specifically binding to glutathione and use thereof |
| IL300283A (en) | 2020-08-04 | 2023-04-01 | Dicerna Pharmaceuticals Inc | Systemic administration of oligonucleotides |
| IL301940A (en) | 2020-10-08 | 2023-06-01 | Dicerna Pharmaceuticals Inc | Selective delivery of oligonucleotides to glial cells |
| EP4271695A2 (en) * | 2020-12-31 | 2023-11-08 | Alnylam Pharmaceuticals, Inc. | 2'-modified nucleoside based oligonucleotide prodrugs |
| US12084662B2 (en) | 2021-04-14 | 2024-09-10 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for modulating PNPLA3 expression |
| AU2022324471A1 (en) | 2021-08-05 | 2024-02-15 | Sanegene Bio Usa Inc. | 1'-alkyl modified ribose derivatives and methods of use |
| EP4405368A1 (en) | 2021-09-22 | 2024-07-31 | Sanegene Bio USA Inc. | 2'-alkyl or 3'- alkyl modified ribose derivatives for use in the in-vivo delivery of oligonucleotides |
| WO2023047338A1 (en) * | 2021-09-24 | 2023-03-30 | Crispr Therapeutics Ag | PRODRUG INCORPORATED sgRNA SYNTHESIS |
| CN118076621A (zh) | 2021-10-05 | 2024-05-24 | 美国圣因生物股份有限公司 | 多羟基化的环戊烷衍生物及使用方法 |
| WO2023102469A2 (en) | 2021-12-01 | 2023-06-08 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for modulating apoc3 expression |
| IL314850A (en) | 2022-02-22 | 2024-10-01 | Sanegene Bio Usa Inc | Ribonucleotide derivatives substituted at the 5' position in the carboxyl group and methods of use |
| KR20250005108A (ko) | 2022-04-15 | 2025-01-09 | 다이서나 파마수이티컬, 인크. | Scap 활성을 조절하기 위한 조성물 및 방법 |
| US20240002857A1 (en) | 2022-05-09 | 2024-01-04 | Sanegene Bio Usa Inc. | Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereof |
| IL317824A (en) | 2022-07-11 | 2025-02-01 | Sanegene Bio Usa Inc | Ribose derivatives modified at the '2' position and methods of use |
| KR20250046303A (ko) | 2022-08-05 | 2025-04-02 | 사네진 바이오 유에스에이 인크. | 안지오텐시노겐 (agt)을 표적화하는 이중 가닥 rna 및 그의 사용 방법 |
| CN120265773A (zh) | 2022-10-14 | 2025-07-04 | 美国圣因生物股份有限公司 | 靶向c3的小干扰rna及其用途 |
| EP4622985A1 (en) * | 2022-11-22 | 2025-10-01 | Ionis Pharmaceuticals, Inc. | Methods for deprotecting and purifying oligonucleotide compounds |
| EP4638743A2 (en) | 2022-12-19 | 2025-10-29 | Sanegene Bio USA Inc. | Small interfering rna targeting cfb and uses thereof |
| US20240309383A1 (en) | 2023-02-24 | 2024-09-19 | Suzhou Sanegene Bio Inc. | Small interfering rna targeting hbv and uses thereof |
| WO2024186673A2 (en) | 2023-03-03 | 2024-09-12 | Sanegene Bio Usa Inc. | Small interfering rna targeting apoc3 and uses thereof |
| CN121866332A (zh) | 2023-06-21 | 2026-04-14 | 美国圣因生物股份有限公司 | 靶向前蛋白转化酶枯草杆菌蛋白酶kexin 9（pcsk9）的双链rna及其使用方法 |
| US20250064939A1 (en) | 2023-07-24 | 2025-02-27 | Sanegene Bio Usa Inc. | Lipid-based enhancement agent for rna delivery and therapy |
| WO2025228441A2 (en) | 2024-04-30 | 2025-11-06 | Sanegene Bio Usa Inc. | Small interfering rna targeting inhbe and uses thereof |
| WO2026017140A2 (en) | 2024-07-18 | 2026-01-22 | Sanegene Bio Usa Inc. | Small interfering rna targeting fxi and uses thereof |
| WO2026041067A2 (en) | 2024-08-20 | 2026-02-26 | Sanegene Bio Usa Inc. | Small interfering rna targeting myostatin (mstn) and uses thereof |
| WO2026046411A1 (en) | 2024-09-02 | 2026-03-05 | Sanegene Bio Usa Inc. | Small interfering rna targeting plasminogen (plg) and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6114513A (en) * | 1990-01-11 | 2000-09-05 | Isis Pharmaceuticals, Inc. | Thiol-derivatized oligonucleotides |
| CA2079109A1 (en) | 1990-03-29 | 1991-09-30 | John A. Latham | Oligonucleotide-transport agent disulfide conjugates |
| US7282590B2 (en) | 2004-02-12 | 2007-10-16 | The Research Foundation Of State University Of New York | Drug conjugates |
| JP2010532786A (ja) | 2007-07-06 | 2010-10-14 | ノースイースタン ユニバーシティ | Ｒｎａ薬剤の両親媒性接合を含む混合ミセルおよびその使用 |
| US8691971B2 (en) | 2008-09-23 | 2014-04-08 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference |
| CA2767253A1 (en) | 2009-07-06 | 2011-01-13 | Ontorii, Inc. | Novel nucleic acid prodrugs and methods of use thereof |
| US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
| WO2013188607A1 (en) * | 2012-06-14 | 2013-12-19 | The Trustees Of The University Of Pennsylvania | One step n-terminal tagging of proteins |
| EP2928876B1 (en) | 2012-12-06 | 2018-01-17 | Merck Sharp & Dohme Corp. | Nucleoside kinase bypass compositions and methods |
| EP2928877B1 (en) | 2012-12-06 | 2020-01-22 | Merck Sharp & Dohme Corp. | Disulfide masked prodrug compositions and methods |
| EP2845607A1 (en) * | 2013-09-09 | 2015-03-11 | University of Vienna | Antisense oligonucleotides with improved pharmacokinetic properties |
| AU2014346658A1 (en) * | 2013-11-06 | 2016-06-02 | Solstice Biologics, Ltd. | Polynucleotide constructs having disulfide groups |
| JP2017522046A (ja) * | 2014-06-06 | 2017-08-10 | ソルスティス バイオロジクス，リミティッド | 生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物 |
-
2017
- 2017-08-23 JP JP2019508973A patent/JP7249080B2/ja active Active
- 2017-08-23 WO PCT/US2017/048239 patent/WO2018039364A1/en not_active Ceased
- 2017-08-23 CA CA3032165A patent/CA3032165C/en active Active
- 2017-08-23 IL IL264685A patent/IL264685B/en unknown
- 2017-08-23 CN CN201780065632.8A patent/CN109890207B/zh active Active
- 2017-08-23 KR KR1020197007856A patent/KR102530513B1/ko active Active
- 2017-08-23 US US16/325,979 patent/US11390642B2/en active Active
- 2017-08-23 EP EP17844358.6A patent/EP3503730B1/en active Active
- 2017-08-23 MX MX2019002075A patent/MX2019002075A/es unknown
- 2017-08-23 IL IL295212A patent/IL295212A/en unknown
- 2017-08-23 AU AU2017315670A patent/AU2017315670B2/en not_active Ceased
- 2017-08-23 CN CN202210479298.3A patent/CN114891053A/zh not_active Withdrawn
-
2019
- 2019-02-21 MX MX2021014769A patent/MX2021014769A/es unknown
-
2022
- 2022-05-09 JP JP2022076983A patent/JP2022106928A/ja not_active Withdrawn
- 2022-06-09 US US17/836,209 patent/US12037358B2/en active Active
- 2022-06-16 AU AU2022204225A patent/AU2022204225A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526555A5 (https=) | ||
| JP6884250B2 (ja) | ペプチドオリゴヌクレオチドコンジュゲート | |
| US20220402883A1 (en) | Compounds and methods for modulating rna function | |
| AU2020200699C1 (en) | Methods and compositions for modulating splicing | |
| US10041074B2 (en) | Euchromatic region targeting methods for modulating gene expression | |
| BR112019026508A2 (pt) | métodos para modificar o splicing do rna | |
| JP7348922B2 (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| RU2017101172A (ru) | Антисмысловые нуклеиновые кислоты | |
| JP2020534826A (ja) | 真核細胞において遺伝子発現をサイレンシングするための非コードｒｎａ分子の特異性の改変 | |
| CN113840602A (zh) | 用于校正异常剪接的组合物和方法 | |
| US20120289457A1 (en) | Peptide oligonucleotide conjugates | |
| CN114007612A (zh) | 用于调节剪接的方法和组合物 | |
| KR20190040033A (ko) | 가역적으로 변형된 올리고뉴클레오티드를 포함하는 조성물 및 그의 용도 | |
| DK1661905T3 (da) | Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype | |
| CA2939822A1 (en) | Crosslinked nucleoside and nucleotide | |
| JP2011529500A5 (https=) | ||
| CN114007611A (zh) | 用于调节剪接的方法和组合物 | |
| JP2015512254A (ja) | オリゴヌクレオチドアナログのボロン酸結合体 | |
| WO2016130929A1 (en) | Targeting oligonucleotides and uses thereof to modulate gene expression | |
| CY1105752T1 (el) | Παραγωγα ιμιδαζοπυριδινης μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα πepιεχουν | |
| ES2586599T3 (es) | Ensayo para cribar compuestos que disminuyen selectivamente el número de células madre de cáncer | |
| Andersen et al. | Efficient RNA-targeting by the introduction of aromatic stacking in the duplex major groove via 5-(1-phenyl-1, 2, 3-triazol-4-yl)-2′-deoxyuridines | |
| Bertrand et al. | The snoRNPs and Related Machines: Ancient Devices That Mediate Maturation of rRNA | |
| JP2021508690A (ja) | ホスホロジチオアートヌクレオシド間結合を含むオリゴヌクレオチド | |
| WO2009113580A1 (ja) | Ｒｎａ選択的ハイブリダイズ試薬及びその利用 |